Company / Cost of Revenue
Fulgent Genetics, Inc. Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$191.8M
FY2025
5-year range
$14.1M / $215.5M
FY2021-FY2025
Trend
+8.8%
vs FY2024
Sector context
#81 of 113
Health Care
What the data says
At $192M, Fulgent Genetics, Inc.'s cost of revenue ranks #33 of 113 in the Health Care sector. Cost of Revenue has fluctuated over the past 10 years, ranging from $0 in FY2019 to $216M in FY2023.
Based on SEC 10-K filings.
$192M in FY2025 with a 5-year CAGR of +16.4%.
Improved from $216M to $192M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +28.8%
- 5-Year CAGR
- +16.4%
- 10-Year CAGR
- -
Sector benchmark
#33 of 113 in Health CareTop 28% of 113This company $191.8M Sector average $11.3B
▼
-98.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +16.4%, indicating consistent growth.
- In FY2025, cost of revenue increased 8.8% year-over-year.
- Ranks #81 out of 113 companies in the Health Care sector.
- Peak cost of revenue was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 5.28 (safe zone, above 2.9 threshold)
- Negative profit margin: -15.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $191.8M | +8.8% |
| FY2024 | $176.3M | -18.2% |
| FY2023 | $215.5M | +140.0% |
| FY2022 | $89.8M | +536.6% |
| FY2021 | $14.1M | -84.3% |
| FY2020 | $89.8M | - |
| FY2019 | $0 | - |
| FY2018 | $0 | -100.0% |
| FY2017 | $8.6M | +813.6% |
| FY2016 | $936.0K | -81.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026